CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal to Study anti-cancer Drug Capivasertib

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-07-28 12:45 GMT | Update On 2024-07-28 12:45 GMT

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved AstraZeneca's protocol amendment proposal to study the anti-cancer drug Capivasertib.

This came after AstraZeneca presented protocol amendment 5, version 6.0 dated 05 March 2024 protocol no. D361DC00001.

Capivasertib is a serine/threonine kinase inhibitor used to treat hormone receptor-positive, HER2-negative, locally advanced, or metastatic breast cancer.

Capivasertib is an inhibitor of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2, and AKT3) and inhibits the phosphorylation of downstream AKT substrates. AKT activation in tumors is a result of activation of upstream signaling pathways, mutations in AKT1, loss of phosphatase and tensin homolog (PTEN) function, and mutations in the catalytic subunit alpha of phosphatidylinositol 3-kinase (PIK3CA).

At the recent SEC meeting for oncology held on July 9, 2024, the expert panel reviewed protocol amendment 5, version 6.0 dated 05 March 2024 protocol no. D361DC00001.

After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.

Also Read: CDSCO Panel Approves Johnson and Johnson's Protocol Amendment Proposal to Study JNJ-77242113

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal to Study anti-cancer Drug Capivasertib

Similar News

Lupin Secures CDSCO Panel Nod for Phase IV Trial of Budesonide-Based COPD Inhaler

165 medical shops licences suspended, seven cancelled in Telangana after Abortion kits raids

Novartis Loses India Patent on Heart Failure Drug Vymada

EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits

CDSCO Launches Separate Online Provision for Subsequent Importers of Medical Devices, IVDs

Aurobindo Pharma arm incorporates new wholly owned subsidiary in Malaysia

Natco Pharma gets USFDA EIR for Kothur Pharma division

Roche to acquire 89bio for up to USD 3.5 billion